Neumora Therapeutics, Inc.

NMRA

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001885522

SEC filings (opens in a new tab)

In the last 90 days, Neumora Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 113 institutions reported holding it in 13F filings for Q2 2026, worth $129.2M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Neumora Therapeutics, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024 All holders in Q2 2024

13F holders of NMRA: Q2 2024 compared with Q3 2024
Measure	Q2 2024	Of which not filed for Q3 2024	Q3 2024	Change
Holders	93	1	104	+12
Shares	63.8M	4.60M	68.7M	+9.45M (+16.0%)
Value	$627.4M	$45.3M	$907.0M	+$324.8M (+55.8%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (23)

Institutions that held Neumora Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to NMRA in Q3 2024
Institution	Shares	Value	% of portfolio
BlackRock, Inc.	6,186,894	$81.7M	0.00%
Siren, L.L.C.	2,606,571	$34.4M	1.72%
Candriam Luxembourg S.C.A.	676,244	$8.93M	0.05%
Deep Track Capital, LP	567,428	$7.50M	0.24%
Capital International Investors	467,180	$6.17M	0.00%
Cerity Partners LLC	242,900	$3.21M	0.01%
Auour Investments LLC	250,000	$2.93M	1.05%
Point72 Asset Management, L.P.	83,077	$1.10M	0.00%
Dark Forest Capital Management LP	55,489	$733.0K	0.09%
Numerai GP LLC	35,239	$465.5K	0.12%
ProShare Advisors LLC	31,790	$419.9K	0.00%
Clarius Group, LLC	16,992	$224.5K	0.02%
Group One Trading, L.P.	15,776	$208.4K	0.01%
Ballentine Partners, LLC	13,441	$177.6K	0.00%
Intech Investment Management LLC	13,275	$175.4K	0.00%
State Board of Administration of Florida Retirement System	12,930	$170.8K	0.00%
Profund Advisors LLC	10,828	$143.0K	0.01%
HSBC Holdings PLC	10,067	$133.5K	0.00%
Acadian Asset Management LLC	4,439	$58.0K	0.00%
Bessemer Group Inc	120	$2.00K	0.00%
Sterling Capital Management LLC	86	$1.14K	0.00%
Ronald Blue Trust, Inc.	38	$374	0.00%
Capital Performance Advisors LLP	11	$145	0.00%

Sold out (11)

Institutions that held Neumora Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of NMRA in Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
Artal Group S.A.	2,824,052	$27.8M
Balyasny Asset Management LLC	380,160	$3.74M
Voloridge Investment Management, LLC	295,973	$2.91M
Marshall Wace, LLP	134,545	$1.32M
Alpine Global Management, LLC	65,728	$646.1K
Caption Management, LLC	45,000	$442.4K
Jefferies Financial Group Inc.	32,500	$319.5K
Two Sigma Advisers, LP	30,800	$302.8K
Verition Fund Management LLC	25,756	$253.2K
Principal Financial Group Inc	16,878	$165.9K
Simplex Trading, LLC	5,221	$51.0K

Not filed for Q3 2024 yet (1)

Institutions that held Neumora Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding NMRA in Q2 2024 that haven't filed for Q3 2024
Institution	Shares, Q2 2024	Value, Q2 2024
BlackRock Inc.	4,603,394	$45.3M